JP2024516183A5 - - Google Patents

Info

Publication number
JP2024516183A5
JP2024516183A5 JP2023565227A JP2023565227A JP2024516183A5 JP 2024516183 A5 JP2024516183 A5 JP 2024516183A5 JP 2023565227 A JP2023565227 A JP 2023565227A JP 2023565227 A JP2023565227 A JP 2023565227A JP 2024516183 A5 JP2024516183 A5 JP 2024516183A5
Authority
JP
Japan
Prior art keywords
composition according
antisense oligonucleotide
mrna
sos1
sos2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026052 external-priority patent/WO2022226377A1/en
Publication of JP2024516183A publication Critical patent/JP2024516183A/ja
Publication of JP2024516183A5 publication Critical patent/JP2024516183A5/ja
Pending legal-status Critical Current

Links

JP2023565227A 2021-04-22 2022-04-22 Sos遺伝子発現を調節するための組成物及び方法 Pending JP2024516183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178420P 2021-04-22 2021-04-22
US63/178,420 2021-04-22
PCT/US2022/026052 WO2022226377A1 (en) 2021-04-22 2022-04-22 Compositions and methods for modulating sos gene expressions

Publications (2)

Publication Number Publication Date
JP2024516183A JP2024516183A (ja) 2024-04-12
JP2024516183A5 true JP2024516183A5 (cg-RX-API-DMAC10.html) 2025-04-30

Family

ID=83723199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565227A Pending JP2024516183A (ja) 2021-04-22 2022-04-22 Sos遺伝子発現を調節するための組成物及び方法

Country Status (6)

Country Link
US (1) US20240182894A1 (cg-RX-API-DMAC10.html)
EP (1) EP4326878A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516183A (cg-RX-API-DMAC10.html)
KR (1) KR20240032184A (cg-RX-API-DMAC10.html)
CN (1) CN117751190A (cg-RX-API-DMAC10.html)
WO (1) WO2022226377A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4396349A4 (en) * 2021-09-02 2025-10-22 Molecular Axiom Llc COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
JP2025521912A (ja) 2022-07-06 2025-07-10 モレキュラー アクシオム エルエルシー 膵臓癌を治療するための組成物及び方法
WO2024138135A2 (en) * 2022-12-22 2024-06-27 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003152A2 (en) * 2002-06-26 2004-01-08 Chiron Corporation Sos1 inhibitors
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
EP2393825A2 (en) * 2009-02-06 2011-12-14 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8802642B2 (en) * 2010-04-28 2014-08-12 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting SMN2 catalytic core
WO2014144148A1 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
EP3169776B1 (en) * 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016161153A2 (en) * 2015-04-01 2016-10-06 The Regents Of The University Of California Prognostic and diagnostic methods for colorectal cancer
PL3484524T3 (pl) * 2016-07-15 2023-03-20 Ionis Pharmaceuticals, Inc. Związki i sposoby modulacji smn2
JP2025521912A (ja) * 2022-07-06 2025-07-10 モレキュラー アクシオム エルエルシー 膵臓癌を治療するための組成物及び方法
WO2024138135A2 (en) * 2022-12-22 2024-06-27 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions

Similar Documents

Publication Publication Date Title
JP7442574B2 (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
US6365345B1 (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role
US20160272970A1 (en) RNA Interference Agents
JP2021533804A5 (cg-RX-API-DMAC10.html)
JPH09510714A (ja) オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性
JP2023537798A5 (cg-RX-API-DMAC10.html)
EP4463553B1 (en) Advanced rna targeting (arnatar)
JP7384033B2 (ja) 一本鎖オリゴヌクレオチド
CN105121452A (zh) 三环核苷和由其制备的寡聚化合物
KR20020033744A (ko) 사람 eg5의 발현을 억제하는 올리고뉴클레오티드
KR20200024793A (ko) 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
JP2024532477A5 (cg-RX-API-DMAC10.html)
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
JPWO2019044974A1 (ja) スモールガイドアンチセンス核酸とその使用
CN114369130B (zh) 修饰的硫代寡核苷酸及其应用
EP4671372A2 (en) Translation-enhancing nucleic acid compounds: Upward regulation 1 coupled with ASO (ACT-UP1) and their uses
AU2024302527A1 (en) Advanced rna targeting (arnatar) for angiotensinogen
JP2026514403A (ja) オリゴヌクレオチド送達担体およびその使用方法
JP2026082999A (ja) Wfdc2の発現を調節するアンチセンス化合物
WO2021157730A1 (ja) 核酸医薬とその使用
JP2025501755A5 (cg-RX-API-DMAC10.html)
WO2021002359A1 (ja) 核酸医薬とその使用
HK40128552A (en) Advanced rna targeting (arnatar)
HK40118739A (en) Advanced rna targeting (arnatar)
HK40118739B (en) Advanced rna targeting (arnatar)